article thumbnail

STAT+: Brain biopsies on ‘vulnerable’ patients at Mount Sinai set off alarm bells at FDA, documents show

STAT

In study documents, Mount Sinai doctors said the biopsies result in “the same amount of tissue loss” and “in effect, the same level of risk” for patients as standard DBS, because they are removing tissue that would otherwise be cauterized.

article thumbnail

PDA revises report on glass container manufacturing

European Pharmaceutical Review

Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types. Specifically, the document covers the development process of glass containers for pharmaceutical products, glass container sampling as well as definition of lots.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Heart Failure Guideline Updates in 2021

Med Ed 101

There are a few important heart failure guideline updates in the works to the American College of Cardiology’s Heart Failure Guidelines, last published in 2013. This document […]. The post Heart Failure Guideline Updates in 2021 appeared first on Med Ed 101.

article thumbnail

Federal Court updates guidance on COVID-19

Pharma in Brief

Also on January 18, 2021, the FC issued a new Practice Direction outlining its Document Retention Schedule, including new plans for the destruction of certain archived documents. Service of Documents. Parties may serve their documents electronically pursuant to the Federal Courts Rules. Document Retention Schedule.

article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

For at least a decade from 2013 until recently, LDL lowering treatments were stuck on a paradigm of just putting people on statins and not getting LDL levels down to certain goals” CETP inhibitors have been around for a while, but they have unfortunately been unsuccessful in getting onto the market commercially. “For

article thumbnail

Novartis agrees $245m settlement over Exforge generics delay

pharmaphorum

The FDA granted full approval to Par’s generic on 28 March, 2013. According to court documents cited by Reuters, annual sales of Exforge in the US were over $400 million before generic versions reached the market.

article thumbnail

Teva faces EU antitrust probe over MS drug Copaxone

pharmaphorum

billion in annual sales it generated during its peak year in 2013. Copaxone (glatiramer) was once a mainstay of Teva’s portfolio with blockbuster sales that the Israel-based pharma fought hard to protect, including releasing a long-acting version to counter cheaper copycat drugs.